Westlake BioPartners Fund I, L.P. bought LTGO

August 10, 2026 · Form 4 insider transaction

Westlake BioPartners Fund I, L.P. bought 1,027,635 shares of LTGO, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 1 day after the transaction.

Direction
Acquired (buy-side)
Shares
1,027,635
Price
N/A
Total value
N/A
Role
CompanyLTGO
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateAugust 10, 2026
Filing dateAugust 11, 2026
Shares owned after5,944,009
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of Series Seed Convertible Preferred Stock, Series A Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.; Shares held directly by Westlake BioPartners Fund I, L.P. ("Fund I"). The general partner of Fund I is Westlake BioPartners GP I, LLC ("GP I"). GP I may be deemed to share voting and dispositive power with regard to the shares held directly by Fund I. Beth Seidenberg ("Seidenberg") is the sole managing director of GP I and has voting and dispositive power over the shares held by Fund I. Seidenberg disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.

View the original Form 4 on SEC EDGAR